Tenax Therapeutics (TENX) news
Recent news
Tenax Therapeutics: Enrollment may resume at each site as amended protocol goes into effect
AInvest Wire · 7d agoTenax Therapeutics - Temporarily pauses level-2 enrollment for TNX-103 in PH-HFPEF - SEC filing
Tenax Therapeutics has temporarily paused level-2 enrollment for its investigational drug TNX-103 in the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFPEF), according to a recent SEC filing . The decision follows ongoing evaluation of the…
AInvest Wire · 7d agoTenax Therapeutics - Requests type C meeting with FDA on levosimendan development - SEC filing
AInvest Wire · 7d agoTenax Therapeutics - To amend level-2 enrollment criteria - SEC filing
Tenax Therapeutics has announced an amendment to the level-2 enrollment criteria for one of its clinical trials, as disclosed in a recent SEC filing. The update is intended to refine patient eligibility standards to improve the precision and relevance of the study outcomes. While specific details…
AInvest Wire · 7d agoTenax Therapeutics Inc: William Blair cuts to market perform rating
AInvest Wire · Aug 11, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.